Pharmacodynamics of antiseizure drugs on behavioural adverse effect

Abstract

Psychiatric disorders comorbid with patients with epilepsy are classified into antiseizure drug induced behavioural adverse reaction, ictal–related and interictal psychiatric disorders. Topiramate, levetiracetam and perampanel have been considered to be high risk antiseizure drugs for antiseizure drug induced behavioural adverse effect (BAE). Neither the diagnosis and treatment for the BAE remained to be clarified. Currently, switching of the causative antiseizure drug is recommended for treatment of BAE. Recently, the pathophysiology of BAE is exploring, and then several hypotheses suggested the similarities of pathomechanisms among ADHD, autism spectrum disorders and BAE.